Calendar of Events
M Mon
T Tue
W Wed
T Thu
F Fri
S Sat
S Sun
1 event,
A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation
by Andrew Mastro, PA-C
A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation
by Andrew Mastro, PA-C
This program is being held in partnership with SDPA. Please visit the link below to be taken to the registration page for this program. Register
1 event,
A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation
by Kathryn Sowerwine, MD
A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation
by Kathryn Sowerwine, MD
Learn more about a treatment option that may help appropriate patients with certain skin diseases driven in part by Type 2 inflammation
1 event,
Diagnosing and Assessing Chronic Spontaneous Urticaria (CSU) and a Treatment Option for Appropriate CSU Patients 12+ Years of Age
by Raj Chovatiya, MD
Diagnosing and Assessing Chronic Spontaneous Urticaria (CSU) and a Treatment Option for Appropriate CSU Patients 12+ Years of Age
by Raj Chovatiya, MD
Learn more about the diagnosis and assessment of chronic spontaneous urticaria (CSU), including its clinical manifestations, diagnostic evaluation, assessment scales, and a treatment option for appropriate CSU patients 12+ years of age.
1 event,
A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation
by Justin Greiwe, MD
A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation
by Justin Greiwe, MD
Learn more about a treatment option that may help appropriate patients with certain skin diseases driven in part by Type 2 inflammation
0 events,
0 events,
0 events,
1 event,
Clinical Case Discussion: An Adult Patient with Uncontrolled Moderate-to-Severe Atopic Dermatitis and a Treatment Option for Appropriate Patients 6+ Months of Age
by Andrew Baker, PA-C
Clinical Case Discussion: An Adult Patient with Uncontrolled Moderate-to-Severe Atopic Dermatitis and a Treatment Option for Appropriate Patients 6+ Months of Age
by Andrew Baker, PA-C
Join us for a program discussing a real-world case of an adult patient with moderate-to-severe atopic dermatitis (AD) and a treatment option that may help appropriate patients with Type 2 inflammation.
1 event,
The Many Faces of Type 2 Inflammation: Unraveling Its Role Across Dermatologic Conditions and a Treatment Option for Appropriate Patients
by Justin Love, PA-C
The Many Faces of Type 2 Inflammation: Unraveling Its Role Across Dermatologic Conditions and a Treatment Option for Appropriate Patients
by Justin Love, PA-C
Learn more about how Type 2 inflammation contributes to the clinical manifestations of atopic dermatitis (AD), prurigo nodularis (PN), and chronic spontaneous urticaria (CSU); which cytokines play key roles in driving this activity; and a treatment option that may help appropriate patients with certain skin diseases driven in part by Type 2 inflammation
1 event,
A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation
by Gina Mangin, PA-C
A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation
by Gina Mangin, PA-C
This program is being held in partnership with SDPA. Please visit the link below to be taken to the registration page for this program. Register
1 event,
Exploring the Pathophysiology of Type 2 Inflammation in Chronic Spontaneous Urticaria (CSU) and a Treatment Option for Appropriate CSU Patients 12+ Years of Age
by Cynthia Trickett, PA-C
Exploring the Pathophysiology of Type 2 Inflammation in Chronic Spontaneous Urticaria (CSU) and a Treatment Option for Appropriate CSU Patients 12+ Years of Age
by Cynthia Trickett, PA-C
Learn more about the evolving understanding of the pathophysiology of chronic spontaneous urticaria (CSU) and a treatment option that may help appropriate CSU patients 12+ years of age.
0 events,
0 events,
0 events,
0 events,
1 event,
DUPIXENT@ (dupilumab) Pediatric Caregiver Story followed by A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation
by Lisa Swanson, MD
DUPIXENT@ (dupilumab) Pediatric Caregiver Story followed by A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation
by Lisa Swanson, MD
Join us for a virtual discussion with an expert speaker and a caregiver of a pediatric patient with atopic dermatitis (AD) to learn more about a treatment option that may help appropriate patients with certain skin diseases driven in part by Type 2 inflammation
2 events,
Beneath the Itch: The Role of Type 2 Inflammation and a Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation
by Ty Hanson, DO
Beneath the Itch: The Role of Type 2 Inflammation and a Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation
by Ty Hanson, DO
Learn more about itch in patients with atopic dermatitis (AD), prurigo nodularis (PN), and chronic spontaneous urticaria (CSU) and a treatment option that may help appropriate patients with certain skin diseases driven in part by Type 2 inflammation
Pearls and Common Challenges for the Diagnosis of Bullous Pemphigoid (BP)
by Matthew Lewis, MD
Pearls and Common Challenges for the Diagnosis of Bullous Pemphigoid (BP)
by Matthew Lewis, MD
Learn more about the diagnosis and assessment of bullous pemphigoid (BP) including clinical manifestations, key laboratory investigations for diagnostic evaluation, consensus-based recommendations and a treatment option for appropriate BP patients
2 events,
Clinical Case Discussion: An Adult Patient with Prurigo Nodularis and a Treatment Option for Appropriate Patients 18+ Years of Age
by Michael Payette, MD
Clinical Case Discussion: An Adult Patient with Prurigo Nodularis and a Treatment Option for Appropriate Patients 18+ Years of Age
by Michael Payette, MD
Join us for a program discussing a real-world case of an adult patient with prurigo nodularis (PN) and a treatment option that may help appropriate patients.
Clinical Case Discussion: A Pediatric Patient with Uncontrolled Moderate-to-Severe Atopic Dermatitis and a Treatment Option for Appropriate Patients 6+ Months of Age
by Dareen Siri, MD
Clinical Case Discussion: A Pediatric Patient with Uncontrolled Moderate-to-Severe Atopic Dermatitis and a Treatment Option for Appropriate Patients 6+ Months of Age
by Dareen Siri, MD
Join us for a program discussing a real-world case of a pediatric patient with moderate-to-severe atopic dermatitis (AD) and a treatment option that may help appropriate patients with Type 2 inflammation.
0 events,
0 events,
0 events,
1 event,
DUPIXENT® (dupilumab) Pediatric Caregiver Story followed by A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation
by Dareen Siri, MD
DUPIXENT® (dupilumab) Pediatric Caregiver Story followed by A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation
by Dareen Siri, MD
Join us for a virtual discussion with an expert speaker and a caregiver of a pediatric patient with atopic dermatitis (AD) to learn more about a treatment option that may help appropriate patients with certain skin diseases driven in part by Type 2 inflammation
2 events,
The Shades of Atopic Dermatitis in Skin of Color and a Treatment Option for Appropriate Patients with Type 2 Inflammation
by Fred Ghali, MD
The Shades of Atopic Dermatitis in Skin of Color and a Treatment Option for Appropriate Patients with Type 2 Inflammation
by Fred Ghali, MD
Learn more about the distinctive ways that atopic dermatitis (AD) may present in patients with skin of color and a treatment option that may help appropriate patients with Type 2 inflammation.
The Many Faces of Type 2 Inflammation: Unraveling Its Role Across Dermatologic Conditions and a Treatment Option for Appropriate Patients.
by Linda Stein Gold, MD
The Many Faces of Type 2 Inflammation: Unraveling Its Role Across Dermatologic Conditions and a Treatment Option for Appropriate Patients.
by Linda Stein Gold, MD
Learn more about how Type 2 inflammation contributes to the clinical manifestations of atopic dermatitis (AD), prurigo nodularis (PN), and chronic spontaneous urticaria (CSU); which cytokines play key roles in driving this activity; and a treatment option that may help appropriate patients with certain skin diseases driven in part by Type 2 inflammation
2 events,
A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation
by Eileen Cheever, PA-C
A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation
by Eileen Cheever, PA-C
This program is being held in partnership with SDPA. Please visit the link below to be taken to the registration page for this program. Register
DUPIXENT@ (dupilumab) Patient Story followed by A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation
by Zakiya Rice, MD
DUPIXENT@ (dupilumab) Patient Story followed by A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation
by Zakiya Rice, MD
Join us for a virtual discussion with an expert speaker and an adult patient with prurigo nodularis (PN) to Learn more about a treatment option that may help appropriate patients with certain skin diseases driven in part by Type 2 inflammation
1 event,
Clinical Case Discussion: An Adult Patient with Uncontrolled Moderate-to-Severe Atopic Dermatitis and a Treatment Option for Appropriate Patients 6+ Months of Age
by Marshall Shuler, MD
Clinical Case Discussion: An Adult Patient with Uncontrolled Moderate-to-Severe Atopic Dermatitis and a Treatment Option for Appropriate Patients 6+ Months of Age
by Marshall Shuler, MD
Join us for a program discussing a real-world case of an adult patient with moderate-to-severe atopic dermatitis (AD) and a treatment option that may help appropriate patients with Type 2 inflammation
0 events,
0 events,
0 events,
1 event,
Pearls and Common Challenges for the Diagnosis of Bullous Pemphigoid (BP)
by Timothy Patton, DO
Pearls and Common Challenges for the Diagnosis of Bullous Pemphigoid (BP)
by Timothy Patton, DO
Learn more about the diagnosis and assessment of bullous pemphigoid (BP) including clinical manifestations, key laboratory investigations for diagnostic evaluation, consensus-based recommendations and a treatment option for appropriate BP patients
1 event,
DUPIXENT®(dupilumab) Patient Story followed by A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation
by Roopen Patel, MD
DUPIXENT®(dupilumab) Patient Story followed by A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation
by Roopen Patel, MD
Join us for a virtual discussion with an expert speaker and an adult patient with atopic dermatitis (AD) to Learn more about a treatment option that may help appropriate patients…
2 events,
A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation
by Douglas DiRuggiero, PA-C
A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation
by Douglas DiRuggiero, PA-C
This program is being held in partnership with SDPA. Please visit the link below to be taken to the registration page for this program. Register
Beneath the Itch: The Role of Type 2 Inflammation and a Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation
by Ben Ehst, MD
Beneath the Itch: The Role of Type 2 Inflammation and a Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation
by Ben Ehst, MD
Learn more about itch in patients with atopic dermatitis (AD), prurigo nodularis (PN), and chronic spontaneous urticaria (CSU) and a treatment option that may help appropriate patients with certain skin…
1 event,
A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation
by Marc Serota, MD
A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation
by Marc Serota, MD
Learn more about a treatment option that may help appropriate patients with certain skin diseases driven in part by Type 2 inflammation